InvestorsHub Logo
Followers 3
Posts 295
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Wednesday, 02/07/2024 9:51:36 AM

Wednesday, February 07, 2024 9:51:36 AM

Post# of 572
In recently posted Hanmi 2024 1Q IR presentation, you can see Tuspetinib data on slide 18. Nothing new there but you have an impression that it is their own data. If Aptose needs a partner to start triplet in 1st line patients, Hanmi would be the best candidate.
https://www.hanmipharm.com/file/admin/ir/1707107587558.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News